$CELC
Celcuity Inc Stock $celc

$celc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017491 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.309M	$1.269M	$811.3K
YoY Change	6.19%	56.42%	44.87%
% of Gross Profit
Research & Development	$13.75M	$11.28M	$6.696M
YoY Change	64.28%	68.43%	199.43%
% of Gross Profit
Depreciation & Amortization	$37.33K	$43.94K	$55.99K
YoY Change	-28.83%	-21.53%	-43.0%
% of Gross Profit
Operating Expenses	$15.06M	$12.55M	$7.508M
YoY Change	56.82%	67.13%	168.92%
Operating Profit	-$15.06M	-$12.55M	-$7.508M
YoY Change	56.82%	67.13%	168.92%
Interest Expense	$1.315M	$1.242M	-$426.8K
YoY Change	188.73%	-390.98%	-1778600.0%
% of Operating Profit
Other Income/Expense, Net	$467.8K	$609.1K	$0.00
YoY Change	-230.02%		-100.0%
Pretax Income	-$14.59M	-$11.94M	-$7.934M
YoY Change	46.45%	50.46%	184.22%
Income Tax
% Of Pretax Income
Net Earnings	-$14.59M	-$11.94M	-$7.934M
YoY Change	46.45%	50.46%	184.22%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.66	-$0.55	-$0.53
Diluted Earnings Per Share	-$0.66	-$0.55	-$531.9K
COMMON SHARES
Basic Shares Outstanding	21.96M shares	21.69M shares	14.92M shares
Diluted Shares Outstanding	21.96M shares	21.68M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.2M	$157.5M	$78.30M
YoY Change	118.57%	101.13%	124.09%
Cash & Equivalents	$32.24M	$33.64M	$78.30M
Short-Term Investments	$114.0M	$123.8M
Other Short-Term Assets	$6.562M	$6.583M	$955.4K
YoY Change	32.39%	589.04%	61.93%
Inventory
Prepaid Expenses	$6.461M	$6.525M
Receivables
Other Receivables
Total Short-Term Assets	$152.8M	$164.1M	$79.44M
YoY Change	112.34%	106.56%	122.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$210.9K	$223.3K	$486.0K
YoY Change	-11.64%	-54.04%	4.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$710.9K	$775.3K	$486.0K
YoY Change	83.51%	59.52%	-25.58%
TOTAL ASSETS
Total Short-Term Assets	$152.8M	$164.1M	$79.44M
Total Long-Term Assets	$710.9K	$775.3K	$486.0K
Total Assets	$153.5M	$164.9M	$79.93M
YoY Change	112.19%	106.27%	119.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.019M	$2.570M	$2.139M
YoY Change	31.01%	20.13%	572.28%
Accrued Expenses	$3.871M	$3.040M	$1.406M
YoY Change	129.97%	116.28%	112.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$980.00	$5.860K
YoY Change	-100.0%	-83.28%	-41.4%
Total Short-Term Liabilities	$7.082M	$5.806M	$3.551M
YoY Change	70.64%	63.51%	203.35%
LONG-TERM LIABILITIES
Long-Term Debt	$35.99M	$35.48M	$14.82M
YoY Change	139.72%	139.33%	148140.0%
Other Long-Term Liabilities	$317.1K	$364.0K	$15.33K
YoY Change		2274.17%	-23.35%
Total Long-Term Liabilities	$36.30M	$35.84M	$14.84M
YoY Change	141.84%	141.54%	49364.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.082M	$5.806M	$3.551M
Total Long-Term Liabilities	$36.30M	$35.84M	$14.84M
Total Liabilities	$43.38M	$41.65M	$18.39M
YoY Change	126.42%	126.47%	1442.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$122.8M	-$108.2M
YoY Change	66.38%
Common Stock	$22.08K	$21.94K
YoY Change	47.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$110.1M	$123.2M	$61.54M
YoY Change
Total Liabilities & Shareholders Equity	$153.5M	$164.9M	$79.93M
YoY Change	112.19%	106.27%	119.79%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$14.59M	-$11.94M	-$7.934M
YoY Change	46.45%	50.46%	184.22%
Depreciation, Depletion And Amortization	$37.33K	$43.94K	$55.99K
YoY Change	-28.83%	-21.53%	-43.0%
Cash From Operating Activities	-$9.662M	-$12.87M	-$5.933M
YoY Change	-14.41%	116.88%	135.3%
INVESTING ACTIVITIES
Capital Expenditures	$4.850K	$6.987K	-$11.64K
YoY Change	-121.11%	-160.03%	-137.64%
Acquisitions
YoY Change
Other Investing Activities	$8.095M	$21.87M	$0.00
YoY Change
Cash From Investing Activities	$8.090M	$21.87M	-$11.64K
YoY Change	-35304.48%	-187965.56%	-61.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	171.5K	$67.95K	-46.29K
YoY Change	-336.59%	-246.79%	-100.18%
NET CHANGE
Cash From Operating Activities	-9.662M	-$12.87M	-5.933M
Cash From Investing Activities	8.090M	$21.87M	-11.64K
Cash From Financing Activities	171.5K	$67.95K	-46.29K
Net Change In Cash	-1.401M	$9.068M	-5.991M
YoY Change	-87.7%	-251.36%	-125.71%
FREE CASH FLOW
Cash From Operating Activities	-$9.662M	-$12.87M	-$5.933M
Capital Expenditures	$4.850K	$6.987K	-$11.64K
Free Cash Flow	-$9.667M	-$12.87M	-$5.921M
YoY Change	-14.19%	117.43%	131.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001603454
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable		usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments		usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023Q1	CELC	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable		usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss		usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss		usd
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q1	CELC	Notes Payable Final Fee NotesPayableFinalFee		usd
CY2022Q4	CELC	Notes Payable Final Fee NotesPayableFinalFee		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38207
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CELCUITY INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2863566
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	16305 36th Avenue North; Suite 100
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Minneapolis
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55446
CY2023Q1	dei	City Area Code CityAreaCode	(763)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	392-0767
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CELC
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21958849	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33639218	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24571557	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	123839227	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	144015954	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	22009	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	22009	usd
CY2023Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	35597	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	33195	usd
CY2023Q1	CELC	Payroll Tax Receivable PayrollTaxReceivable	38263	usd
CY2022Q4	CELC	Payroll Tax Receivable PayrollTaxReceivable	203665	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6525368	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6344157	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	164099682	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	175190537	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	223343	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	260294	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	551933	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246266	usd
CY2023Q1	us-gaap	Assets Assets	164874958	usd
CY2022Q4	us-gaap	Assets Assets	175697097	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2569913	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2627076	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	981	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2449	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	194895	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	191749	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3040178	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4060280	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5805967	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6881554	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	363961	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61002	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	35478262	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	34983074	usd
CY2023Q1	us-gaap	Liabilities Liabilities	41648190	usd
CY2022Q4	us-gaap	Liabilities Liabilities	41925630	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1095873	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1095873	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1120873	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1120873	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	1096	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1121	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21941372	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21941372	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21667250	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21667250	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	21941	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21667	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	231439035	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	230045566	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108235304	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-96296887	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123226768	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	133771467	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164874958	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175697097	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11278493	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6696313	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1269044	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	811292	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	12547537	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7507605	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12547537	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7507605	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1242012	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	435001	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1851132	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8159	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	609120	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-426842	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11938417	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7934447	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11938417	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934447	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21680877	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14917187	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	133771467	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1273282	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	127922	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7486	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11938417	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123226768	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	68710477	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	756271	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7414	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934447	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	61539715	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11938417	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7934447	usd
CY2023Q1	us-gaap	Depreciation Depreciation	43938	usd
CY2022Q1	us-gaap	Depreciation Depreciation	55989	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1273282	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	756271	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	57004	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	95012	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	438184	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	102086	usd
CY2023Q1	CELC	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	438	usd
CY2022Q1	CELC	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	-58	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	1697811	usd
CY2023Q1	CELC	Increase Decrease In Payroll Tax Receivable IncreaseDecreaseInPayrollTaxReceivable	-165402	usd
CY2022Q1	CELC	Increase Decrease In Payroll Tax Receivable IncreaseDecreaseInPayrollTaxReceivable	-105730	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	181211	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	40205	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-8545	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	513091	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1020102	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	413499	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12867838	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5933032	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3125462	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	25000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6987	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11635	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21867551	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11635	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	127922	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7414	usd
CY2023Q1	CELC	Payments For Registration Statement Costs PaymentsForRegistrationStatementCosts	55789	usd
CY2022Q1	CELC	Payments For Registration Statement Costs PaymentsForRegistrationStatementCosts	52244	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2716	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1469	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1458	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67948	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-46288	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9067661	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5990955	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24571557	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	84286381	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	33639218	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78295426	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	746824	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	237903	usd
CY2023Q1	CELC	Offering And Registration Statement Costs Included In Accounts Payable OfferingAndRegistrationStatementCostsIncludedInAccountsPayable	2402	usd
CY2022Q1	CELC	Offering And Registration Statement Costs Included In Accounts Payable OfferingAndRegistrationStatementCostsIncludedInAccountsPayable	104237	usd
CY2022Q1	CELC	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	22987	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zvpTWLA4leug" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zFBlO7KDLNi3">Accounting Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z0C2l4S06Zu2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zC91pAD21PGi">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	123839227	usd
CY2023Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	13899	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	123853126	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	144015954	usd
CY2022Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	71156	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	144087110	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	355578	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	2200000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21667250	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1120873	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	65000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21941372	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1095873	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.798	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	increase automatically on January 1 of each year from 2024 through 2027 by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding December 31.
CY2023Q1	CELC	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear	2781277	usd
CY2023Q1	CELC	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognized Next Twelve Months EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedNextTwelveMonths	2291390	usd
CY2023Q1	CELC	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Two Year EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear	1474943	usd
CY2023Q1	CELC	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Three Years EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinThreeYears	435113	usd
CY2023Q1	CELC	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Four Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears	6198	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6988921	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1273282	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	756271	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	35000000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	35000000	usd
CY2023Q1	CELC	Payment In Kind Interest Debt PaymentInKindInterestDebt	1193259	usd
CY2022Q4	CELC	Payment In Kind Interest Debt PaymentInKindInterestDebt	755075	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	653555	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	707001	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	61442	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	65000	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	35478262	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	34983074	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	13572473	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	18096629	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4524157	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	36193259	usd

Files In Submission

Name	View Source	Status
celc-20230331_cal.xml	Edgar Link	unprocessable
celc-20230331_def.xml	Edgar Link	unprocessable
0001493152-23-017491-index-headers.html	Edgar Link	pending
0001493152-23-017491-index.html	Edgar Link	pending
0001493152-23-017491.txt	Edgar Link	pending
0001493152-23-017491-xbrl.zip	Edgar Link	pending
celc-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
celc-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
celc-20230331_pre.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELC
Celcuity Inc Stock $celc

2023 Q2 Form 10-Q Financial Statement

#000149315223017491 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC Celcuity Inc Stock $celc

2023 Q2 Form 10-Q Financial Statement

#000149315223017491 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC
Celcuity Inc Stock $celc